SCHEMBL6987334

SCHEMBL6987334

C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCCN1CCOC(=O)[C@@H]1C

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 20/20 0.71
ERBB2 P04626 6/20 0.71
ERBB3 P21860 3/20 0.71
KIT P10721 2/20 0.71
SRC P12931 2/20 0.71
ERBB4 Q15303 2/20 0.71
KDR P35968 2/20 0.71
BMPR1B O00238 1/20 0.71
CIT O14578 1/20 0.71
MAP2K7 O14733 1/20 0.71
GAK O14976 1/20 0.71
EPHB6 O15197 1/20 0.71
MAP3K7 O43318 1/20 0.71
RIPK2 O43353 1/20 0.71
STK17B O94768 1/20 0.71
STK10 O94804 1/20 0.71
ABL1 P00519 1/20 0.71
LCK P06239 1/20 0.71
FYN P06241 1/20 0.71
YES1 P07947 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7684212 1.00 EGFR (0.71) EGFRERBB2ERBB3KITSRC
SCHEMBL6992854 0.98 EGFR (0.74) EGFRERBB2ERBB3KITSRC
SCHEMBL6994284 0.98 EGFR (0.74) EGFRERBB2ERBB3KITSRC
SCHEMBL7688276 0.98 EGFR (0.74) EGFRERBB2ERBB3KITSRC
SCHEMBL7263390 0.87 EGFR (0.75) EGFRERBB2SRCERBB4GAK
SCHEMBL7263386 0.87 EGFR (0.75) EGFRERBB2SRCERBB4GAK
SCHEMBL7263382 0.87 EGFR (0.75) EGFRERBB2SRCERBB4GAK
SCHEMBL7682124 0.86 EGFR (0.55) EGFRERBB2ERBB3KITSRC
SCHEMBL7264254 0.84 EGFR (0.73) EGFRERBB2SRCERBB4GAK
SCHEMBL7264246 0.84 EGFR (0.73) EGFRERBB2SRCERBB4GAK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1322645-A2 QUINAZOLINES, MEDICAMENTS, WHICH CONTAIN THESE COMPOUNDS AND WHICH ARE EFFECTIVE AS TYROSINE KINASE INHIBITORS, THEIR USE, AND METHODS FOR THE PRODUCTION THEREOF Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2003-07-02 EP claimed
US-6403580-B1 HAVING AN INHIBITORY EFFECT ON SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES, THE USE THEREOF FOR TREATING DISEASES, PARTICULARLY TUMORAL DISEASES, DISEASES OF THE LUNGS AND RESPIRATORY TRACT, AND THE PREPARATION THEREOF. BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-06-11 US claimed
WO-2002018375-A1 QUINAZOLINES, MEDICAMENTS, WHICH CONTAIN THESE COMPOUNDS AND WHICH ARE EFFECTIVE AS TYROSINE KINASE INHIBITORS, THEIR USE, AND METHODS FOR THE PRODUCTION THEREOF BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-03-07 WO claimed
EP-1322645-A2 QUINAZOLINES, MEDICAMENTS, WHICH CONTAIN THESE COMPOUNDS AND WHICH ARE EFFECTIVE AS TYROSINE KINASE INHIBITORS, THEIR USE, AND METHODS FOR THE PRODUCTION THEREOF Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2003-07-02 EP disclosed
US-6403580-B1 HAVING AN INHIBITORY EFFECT ON SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES, THE USE THEREOF FOR TREATING DISEASES, PARTICULARLY TUMORAL DISEASES, DISEASES OF THE LUNGS AND RESPIRATORY TRACT, AND THE PREPARATION THEREOF. BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-06-11 US disclosed
WO-2002018375-A1 QUINAZOLINES, MEDICAMENTS, WHICH CONTAIN THESE COMPOUNDS AND WHICH ARE EFFECTIVE AS TYROSINE KINASE INHIBITORS, THEIR USE, AND METHODS FOR THE PRODUCTION THEREOF BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-03-07 WO disclosed